NAD+-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer

Cancer Prevention Research

Volumn 1, Issue 4, 2008, Pages 241-249

  Hughes, Duncan ^a   Otani, Taisuke ^a   Yang, Peiying ^b   Newman, Robert A ^b   Yantiss, Rhonda K ^a   Altorki, Nasser K ^a   Port, Jeff L ^a   Yan, Min ^c   Markowitz, Sanford D ^c   Mazumdar, Madhu ^a   Tai, Hsin Hsiung ^d   Subbaramaiah, Kotha ^a   Dannenberg, Andrew J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d University of Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE; CYCLOOXYGENASE 2; ISOMERASE; PROSTAGLANDIN; PROSTAGLANDIN E SYNTHASE; PTGS2 PROTEIN, HUMAN;

ANIMAL; ARTICLE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LIPID METABOLISM; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; MOUSE; MOUSE MUTANT; PHYSIOLOGY;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CYCLOOXYGENASE 2; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; INTRAMOLECULAR OXIDOREDUCTASES; LIPID METABOLISM; LUNG NEOPLASMS; MICE; MICE, KNOCKOUT; PROSTAGLANDINS;

EID: 57249089707     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0055     Document Type: Article

References (51)

1. Lupulescu A. Prostaglandins, their inhibitors and cancer. Prostaglandins Leukot Essent Fatty Acids 1996;54:83-94.
2. Bennett A, Carroll MA, StamfordIF, Whimster WF, Williams F. Prostaglandins and human lung carcinomas. Br J Cancer 1982;46:888-93.
3. McLemore TL, HubbardWC, Litterst CL, et al. Profiles of prostaglandin biosynthesis in normal lung andtumor tissue from lung cancer patients. Cancer Res 1998;48:3140-7.
4. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med1993; 122:518-23.
5. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, andmolecular biology. Annu Rev Biochem 2000;69:145-82.
6. Subbaramaiah K, Telang N, Ramonetti JT, et al. Transcription of cyclooxygenase-2 is enhancedin transformedmammary epithelial cells. Cancer Res 1996;56:4424-9.
7. Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase- 2 in human neoplasia: rationale and promise. Cancer Cell 2003;4:431-6.
8. Jakobsson PJ, Thoren S, Morgenstern R, Samuelsson B. Identification of human prostaglandin E synthase: a microsomal, glutathionedependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci U S A 1999;96:7220-5.
9. Huang M, Stolina M, Sharma S, et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 1998;58:1208-16.
10. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A. Expression of cyclooxygenase- 2 in human lung carcinoma. Cancer Res 1998; 58:4997-5001.
11. Yoshimatsu K, Altorki NK, Golijanin D, et al. Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin Cancer Res 2001;7: 2669-74.
12. Yoshimatsu K, Golijanin D, Paty PB, et al. Inducible microsomal prostaglandin E synthase is overexpressedin colorectal adenomas and cancer. Clin Cancer Res 2001;7:3971-6.
13. Cohen EG, AlmahmeedT, Du B, et al. Microsomal prostaglandin E synthase-1 is overexpressed in headandneck squamous cell carcinoma. Clin Cancer Res 2003;9:3425-30.
14. Tai HH, Ensor CM, Tong M, Zhou H, Yan F. Prostaglandin catabolizing enzymes. Prostaglandins Other LipidMed iat 2002;68/69:483-93.
15. PichaudF, Delage-Mourroux R, Pidoux E, Jullienne A, Rousseau-Merck MF. Chromosomal localization of the type-I 15-PGDH gene to 4q34-q35. Hum Genet 1997;99:279-81.
16. Ensor CM, Tai HH. NAD+-dependent 15-hydroxyprostaglandin dehydrogenase. A key enzyme for the catabolism of prostaglandins. J Lipid Mediat Cell Signal 1995;12:313-9.
17. Ding Y, Tong M, Liu S, Moscow JA, Tai HH. NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis 2005;26:65-72.
18. Yan M, Rerko RM, Platzer P, et al. 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-β-induced suppressor of human gastrointestinal cancers. Proc Natl AcadS ci U S A 2004;101:17468-73.
19. BacklundMG, Mann JR, Holla VR, et al. 15-Hydroxyprostaglandin dehydrogenase is down-regulatedin colorectal cancer. J Biol Chem 2005;280: 3217-23.
20. Gee JR, Montoya RG, KhaledH M, Sabichi AL, Grossman HB. Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional andsquamous cell carcinoma of the bladder. Urol Oncol 2003; 21:266-70.
21. Wolf I, O'Kelly J, Rubinek T, et al. 15-Hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res 2006;66: 7818-23.
22. 2 andp romotes cancer progression. Cancer Res 2006;66:6649-56.
23. Myung SJ, Rerko RM, Yan M, et al. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl AcadSci U S A 2006;103:12098-102.
24. 2 by prostaglandin dehydrogenase is essential for remodeling the ductus arteriosus. Nat Med 2002;8: 91-2.
25. Subbaramaiah K, Yoshimatsu K, Scherl E, et al. Microsomal prostaglandin E synthase-1 is overexpressed in inflammatory bowel disease. Evidence for involvement of the transcription factor Egr-1. J Biol Chem 2004;279:12647-58.
26. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-75.
27. Tong M, Tai HH. Induction of NAD+-linked15-hydroxyprostaglandin dehydrogenase expression by androgens in human prostate cancer cells. Biochem Biophys Res Commun 2000;276:77-81.
28. Yang P, Chan D, Felix E, et al. Determination of endogenous tissue inflammation profiles by LC/ MS/MS: COX- andLOX-d erivedbio active lipids. Prostaglandins Leukot Essent Fatty Acids 2006; 75:385-95.
29. Hollander M, Wolfe D. Nonparametric statistical methods. New York: Wiley-Liss; 1973.
30. Piper PJ, Vane JR, Wyllie JH. Inactivation of prostaglandins by the lungs. Nature 1970;225:600-74.
31. 2 induces transcriptional repressors ZEB1 andSnail in non-small cell lung cancer. Cancer Res 2006;66:5338-45.
32. 2 in human colon cancer cells. Cancer Res 1998;58:362-6.
33. Goodwin JS, Bankhurst AD, Messner RP. Suppression of human T-cell mitogenesis by prostaglandin. Existence of a prostaglandin producing suppressor cell. J Exp Med1977;146:1719-34.
34. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93: 705-16.
35. Gensch C, Clever Y, Werner C, Hanhoun M, Bohm M, Laufs U. Regulation of endothelial progenitor cells by prostaglandin E1 via inhibition of apoptosis. J Mol Cell Cardiol 2007;42:670-7.
36. Weiss TW, Mehrabi MR, Kaun C, et al. Prostaglandin E1 induces vascular endothelial growth factor-1 in human adult cardiac myocytes but not in human adult cardiac fibroblasts via a cAMP-dependent mechanism. J Mol Cell Cardiol 2004;36:539-46.
37. Siendones E, Jimenez-Gomez Y, Montero JL, Gomez-Diaz C, Villalba JM, Muntane J. PGE1 abolishes the mitochondrial-independent cell death pathway induced by D-galactosamine in primary culture of rat hepatocytes. J Gastroenterol Hepatol 2005;20:108-16.
38. 2α stimulates motility andinvasi on in colorectal tumor cells. Int J Cancer 2007;121:734-40.
39. 2α receptor in human endometrial adenocarcinoma: regulation of proliferation by activation of the epidermal growth factor receptor andmitogen-activated protein kinase signaling pathways. J Clin Endocrinol Metab 2004; 89:986-93.
40. 2α-FP receptor interaction in human endometrial adenocarcinomas. Cancer Res 2005;65:7707-16.
41. 2α serve as an anti-apoptotic factor against apoptosis induced by tumor necrosis factor-α in mouse 3T3-L1 preadipocytes. Biosci Biotechnol Biochem 2006;70: 2145-53.
42. Stolina M, Sharma S, Lin Y, et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 andIL-12 synthesis. J Immunol 2000;164:361-70.
43. Yang L, Huang Y, Porta R, et al. Host andd irect antitumor effects andprofoundred uction in tumor metastasis with selective EP4 receptor antagonism. Cancer Res 2006;66:9665-72.
44. Ensor CM, Tai HH. 15-Hydroxyprostaglandin dehydrogenase. J Lipid Mediat Cell Signal 1995;12: 313-9.
45. Yang L, Amann JM, Kikuchi T, et al. Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small cell lung cancer. Cancer Res 2007;67: 5587-93.
46. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52.
47. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-84.
48. Altorki NK, Keresztes RS, Port JL, et al. Celecoxib, a selective cyclooxygenase-2 inhibitor, enhances the response to preoperative paclitaxel andcar boplatin in early-stage non-small-cell lung cancer. J Clin Oncol 2003;21:2645-50.
49. Edelman MJ, Watson D, Wang X, et al. Eicosanoid modulation in advanced lung cancer: Cyclooxygenase- 2 expression is a positive predictive factor for celecoxib + chemotherapy-Cancer andLeukemia Group B trial 30203. J Clin Oncol 2008;26: 848-55.
50. Solomon SC, Pfeffer MA, McMurray JJV, et al. Effect of celecoxib on cardiovascular events and bloodpressure in two trials for the prevention of colorectal adenomas. Circulation 2006;114:1028-35.
51. 2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase. Mol Pharmacol 2007;71:1715-20.